Vincent Rajkumar: ASCO24 myeloma papers that I will be highlighting

Vincent Rajkumar shared a post on X:

”First of the NEJM ASCO24 myeloma papers that I will be highlighting.

Congratulations Vania Hungria, Marivi Mateos, Thanos Dimopoulos et al.

Belantamab will make a comeback. With proper dosing frequency this will be an important drug for myeloma. I this head to head triplet vs triplet trial, it had better PFS and MRD- rate than Dara.”

Read further.
Source: Vincent Rajkumar/X

Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group.  He also chairs the Board of directors of  The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.